top of page

Following a drop in performance, the British company pulls COVID-19 off the market




According to a statement posted Monday, the Avacta Group has temporarily ceased sales of its COVID-19 lateral flow test in order to replace the antibody in the device and guarantee that the device's performance in detecting the Omicron variation is comparable to that of prior strains.


In a press statement, the business started, "Our dedication to exclusively deliver high quality, high-performance diagnostic tests has led us to the prudent choice to suspend all advertising of the AffiDX® lateral flow antigen test." Omicron has been detected in patient samples using Avacta's AffiDX antigen assay, but only in situations when the viral level is high.


The antibodies, which were used in the test in conjunction with a proprietary solution, identify Omicron with the same sensitivity as the Delta version but are impacted by the extra Omicron mutations. According to the article, the corporation is now working to replace the antibody in order to improve its detection of the current variation.


11 Jan 2022

 
 
 

Comments


Contact us

Letter to Editor-In-Chief
Editor@capitoltimesmedia.com

For Advertising in
Capitol Times Magazine:

ads@capitoltimesmedia.com

Capitol Times magazine Issue 5
Capitol times magazine 9
Capitol times magazine 10

Join our mailing list

FOLLOW US

Disclaimer:

The views and opinions expressed in the articles or Interviews published in this magazine are solely those of the respective authors and do not necessarily reflect the official policy or position of the Capitol Times magazine or Capitol Times Media , its editors, or its staff. The authors are solely responsible for the content of their articles. The magazine strives to provide a platform for diverse voices and opinions, and we value the principle of free expression. The magazine assumes no responsibility or liability for any errors or omissions in the content of the articles. In no event shall the Capitol Times magazine or Capitol Times Media be liable for any special, direct, indirect, or incidental damages. Furthermore, the inclusion of advertisements or sponsored content in Capitol Times magazine does not constitute an endorsement or guarantee of the products, services, or views promoted by the advertisers. Readers are encouraged to conduct their own research and exercise caution when making decisions based on advertisements or sponsored content featured in this publication.

Thank you for reading and engaging with our publication. Your feedback is valuable to us as we continue to provide a platform for thought-provoking content and diverse perspectives.

© 2025 by Capitol Times Media LLC - Privacy Policy

  • X
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
bottom of page